全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Briot T , Roger E , Lautram N ...
来源:[J].International Journal of Nanomedicine(IF 3.463), 2017, Vol.Volume 12, pp.8427-8442DOAJ
摘要:Thomas Briot,1,2 Emilie Roger,1 Nolwenn Lautram,1 Alexis Verger,1 Anne Clavreul,3,4 Frederic Lagarce1,2 1Micro & Nanomédecines Translationelles – MINT, UNIV Angers, INSERM 1066, CNRS 6021, Université Bretagne Loire, MINT IBS-CHU, 2Pharmacy Department, University Hospital of Angers, 3Neurosurgery Department, University Hospital of Angers, 4CRCINA, INSERM, Université de Nantes, Université d’Angers, Angers, France Abstract: Decitabine...
作者:Dou L , Xu Q , Wang M ...
来源:[J].OncoTargets and Therapy(IF 2.073), 2019, Vol.Volume 12, pp.5013-5023DOAJ
摘要:... 2Department of Hematology, Hainan Branch of Chinese PLA General Hospital, Sanya, Hainan 572013, People’s Republic of China*These authors contributed equally to this work Purpose: The chemotherapeutic regimen DCAG (decitabine with cytarabine, aclarubicin hydrochloride, ...
作者:Li S , Xue L , Wang M ...
来源:[J].OncoTargets and Therapy(IF 2.073), 2019, Vol.Volume 12, pp.5627-5638DOAJ
摘要:...Method: A combined treatment protocol of CAR-T cell with decitabine (DAC) to treat B cell lymphoma was developed and tested on lymphoma cell lines first, and then efficacy and the underlying mechanism were investigated. After ethical approval was granted, the combined tre...
作者:Lingyun Wu , Wenhui Shi , Xiao Li ...
来源:[J].Journal of Translational Medicine(IF 3.459), 2016, Vol.14 (1)Springer
摘要:Abstract(#br) Background(#br)Despite the efficacy of decitabine treatment in myelodysplastic syndrome (MDS), no definite predictor of response is known. In this study, we investigated whether the expression levels of human equilibrative nucleoside transporter 1 ( hENT1 ), hENT2 ,...
作者:Olga Grishina , Claudia Schmoor , Konstanze Döhner ...
来源:[J].BMC Cancer(IF 3.333), 2015, Vol.15 (1)Springer
摘要:... Approval of decitabine (DAC) in the European Union (EU) in 2012 for the treatment of patients with AML ≥65 years marks the potential for hypomethylating agents in elderly AML. Nevertheless the situation is dissatisfactory and the quest for novel treatment approaches, incl...
作者:Li-juan Tang , Guo-kang Sun , Ting-juan Zhang ...
来源:[J].Cancer Cell International(IF 2.093), 2019, Vol.19 (1), pp.1-11DOAJ
摘要:... In addition, decitabine (DAC) has made great progress in the treatment of AML in recent years, but DAC resistance is still common phenomenon and the mechanism of resistance is still unclear. We further analyze the influences of miR-29c to leukemic cells treated with DAC. Meth...
作者:Moe Tamura , Taishi Yonezawa , Xiaoxiao Liu ...
来源:[J].Scientific Reports(IF 2.927), 2019, Vol.9 (1), pp.1-14DOAJ
摘要:Abstract Decitabine is a DNA methyltransferase inhibitor and is considered a promising drug to treat myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) with p53 mutations. However, whether loss of p53 in fact increases the response of MDS/AML cells to decitabine rem...
作者:Veerauo V Konkankit , Won Kim , Richard C Koya ...
来源:[J].Journal of Translational Medicine(IF 3.459), 2011, Vol.9 (1)Springer
摘要:...(#br) Methods(#br)We hypothesized that treatment with the demethylating agent, decitabine, would upregulate the expression of TRA on tumor cells, thereby facilitating enhanced surveillance by TRA-specific T cells.(#br) Results and Discussion(#br)Treatment of human glioma cells...
作者:Mixue Xie , Qi Jiang , Yanhui Xie
来源:[J].Clinical Lymphoma Myeloma and Leukemia(IF 1.667), 2015, Vol.15 (1), pp.22-28Elsevier
摘要:Abstract(#br)The hypomethylating agents decitabine and azacitidine have been found to improve the outcome of patients with myelodysplastic syndrome (MDS); however, the clinical choice between them is controversial. Therefore, this meta-analysis was performed to compare the effica...
作者:Zhang N , Liu Y , Wang Y ...
来源:[J].Drug Design, Development and Therapy(IF 3.486), 2017, Vol.Volume11, pp.969-983DOAJ
摘要:... Methods: In this study, we determined the effect of decitabine, a DNA methyltransferase inhibitor, on TGF-Β1-induced EMT in non-small-cell lung cancer (NSCLC) PC9 and A549 cells. We also assessed the involvement of the miR-200/ZEB axis. Results: Decitabine reversed TGF-Β...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×